Cargando…
Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect?
Bisphosphonates are recommended in the treatment of osteoporosis and some cancers, in which case they prevent the appearance of bone metastasis. The patients taking bisphosphonates are at increased risk of developing bisphosphonate-related osteonecrosis of jaw (BRONJ) which is characterised by the p...
Autores principales: | Petcu, Eugen B, Ivanovski, Saso, Wright, Robert G, Slevin, Mark, Miroiu, Rodica I, Brinzaniuc, Klara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479027/ https://www.ncbi.nlm.nih.gov/pubmed/22770117 http://dx.doi.org/10.1186/1746-1596-7-78 |
Ejemplares similares
-
Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect
por: Sharma, Dileep, et al.
Publicado: (2013) -
Bisphosphonate-related osteonecrosis of the jaws (Bronj)
por: Beninati, Francesco, et al.
Publicado: (2013) -
Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males
por: Kwon, Yong-Dae, et al.
Publicado: (2016) -
Development of animal model for Bisphosphonates-related osteonecrosis of the jaw (BRONJ)
por: Jang, Hyo-Won, et al.
Publicado: (2015) -
Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ)()
por: Kishimoto, Hiromitsu, et al.
Publicado: (2019)